期刊文献+

吉非替尼微丸胶囊的研制 被引量:2

Preparation of Capsules Filled with Gefitinib Pellets
原文传递
导出
摘要 利用流化床包衣技术,在空白丸芯上依次包主药层和包衣层,制成吉非替尼微丸后装填胶囊,并采用正交设计优化包衣工艺参数。考察了自制品及原研品(易瑞沙)在pH 1盐酸和pH 6.8磷酸盐缓冲液(PBS)中的溶出度。结果两种剂型在盐酸中30 min的溶出率均高于90%,而在PBS中则低于20%。通过破坏性试验和影响因素试验初步评价了自制品的稳定性。结果表明,经强酸、强碱、氧化或光照破坏后,测得的有关物质均小于0.6%;在高温、强光及高湿条件下放置10 d,性状、含量、有关物质及溶出度无明显改变。 The blank pill core was sequentially coated on the active ingredient layer and inactive ingredients layer by fluidized bed coating method to obtain the gefitinib pellets. The prepared pellets were filled into the capsules. The parameters of the coating process were optimized by orthogonal design. The in vitro dissolution behaviors in pH 1 hydrochloric acid and pH 6.8 phosphate buffer (PBS) of the product and the original preparation (Iressa) were investigated. The results showed that the dissolution at 30 rain of both preparations were over 90 % in hydrochloric acid while in PBS were below 20 %. The destructive test and influencing factor test were carried out to evaluate the preliminary stability of the product. The results showed that the related substances of the product after destruction by acid, alkali, oxidation or light were less than 0.6 %. After storing the pellets under high temperature, light or high humidity condition for 10 d, the appearance, content, related substances and dissolution had no significant changes.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2013年第11期1123-1126,共4页 Chinese Journal of Pharmaceuticals
关键词 吉非替尼 微丸 胶囊 流化床包衣 gefitinib pellet capsule fluidized bed coating
  • 相关文献

参考文献4

  • 1Golsteyn RM. Gefitinib does not increase survival in lungcancer patients [J]. Drug Discov Today, 2005,10(6): 381.
  • 2徐朝江,王卓,姚远兵.吉非替尼用于肺癌治疗[J].世界临床药物,2006,27(4):233-237. 被引量:3
  • 3Jones HK, Stafford LE, Swaisland HC, et al. A sensitiveassay for ZD1839 (Iressa) in human plasma by liquid-liquidextraction and high performance liquid chromatography withmass spectrometric detection: validation and use in Phase Iclinical trials [J]. J Pharm Biomed Analysis, 2002, 29(1-2):221-228.
  • 4Faivre L, Gomo C,Mir O, et al. A simple HPLC-UY methodfor the simultaneous quantification of gefitinib and erlotinib inhuman plasma [J]. J Chromatogr B Analyt Techno] BiomedLife Sci, 879 (23): 2345-2350.

二级参考文献2

共引文献2

同被引文献20

  • 1李海刚,王东凯.注射用克拉霉素脂质体的制备及其包封率的测定[J].中国抗生素杂志,2006,31(10):635-637. 被引量:8
  • 2SAGARIKA BOSE, ROBIN H. Bogner. Solventless Pharma-ceutical Coating Processes:A Review [J]. Pharmaceutical De-velopment and Technology,2007,12(2) :115-131.
  • 3S DHUPPE,S S MITKARE,D M SAKARKAR. Recent Tech-niques of Pharmaceutical Solvent less Costing: A review [J].International journal of pharmaceutical sciences and research,2012,3(7);1976-1986.
  • 4DOROTHEA SAUER, MATTEO CEREA, JAMES DINU-NAIO’et al. Dry powder coating of pharmaceuticals : A review[J]. International Journal of Pharmaceutics, 2013 , 457 ( 2 ):488-502.
  • 5CAO QR,LIU Y’XUWJ,et al. Enhanced oral bioavailabilityof novel mucoadhesive pellets containing valsartan preparedby a dry powder-coating technique [J]. International Journalof Pharmaceutics, 2012 ,434(1-2) : 325-333.
  • 6SIMON ENSSLIN, KLAUS PETER MOLL, KURT PAU-LUS,et al. New insight into modified release pellets-Internalstructure and drug release mechanism [J]. Journal of Con-trolled Release.2008,128(2) :149-156.
  • 7GAQ C’HVANG J,JIAO Y,et al. In vitro release and in vi-vo absorption in beagle dogs of meloxicam from Eudragit FS30 D-coated pellets [J]. International Journal of Pharmaceu-tics,2006 ,322(1-2) : 104-112.
  • 8关世侠,杨民,李海刚.头孢呋辛酯掩味微丸的制备[J].中国药房,2008,19(22):1723-1724. 被引量:4
  • 9张红梅.儿童用药剂的现状及开发[J].天津药学,1998,10(1):58-59. 被引量:2
  • 10涂家生,王平.克拉霉素微球的制备及其评价[J].中国药师,1999,2(1):5-6. 被引量:12

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部